colistin (sulfate; CAS# 1264-72-8) and sulbactam (CAS# 68373-14-8) were obtained from Sigma-Aldrich (Saint Louis, USA). Stock solutions (5.12 mg/ml of each) were prepared using Milli-Q water and filtered through 0.22-μm syringe filters (Sartorius, Melbourne, VIC, Australia). All organic solvents used in metabolite sample extraction and the mobile phase of liquid chromatography (LC) were LC–mass spectrometry (LC-MS) grade and purchased from Merck Millipore (Bayswater, VIC, Australia).
A. baumannii AB090342 was collected from a patient (60–65 years old) with ventilator-associated pneumonia who received intravenous colistimethate sodium (150-mg colistin base activity every 12 h for 10 days) (Han et al., 2018a (link)). The patient was enrolled in a clinical study that was approved by the institutional review board of Sir Run Run Shaw Hospital (Zhejiang, China) and Huashan Hospital (Shanghai, China), and an informed consent form was obtained from the patient before the study. Minimum inhibitory concentrations of colistin (0.5 mg/L) and sulbactam (128 mg/L) were determined by broth microdilution.
A. baumannii AB090342 was collected from a patient (60–65 years old) with ventilator-associated pneumonia who received intravenous colistimethate sodium (150-mg colistin base activity every 12 h for 10 days) (Han et al., 2018a (link)). The patient was enrolled in a clinical study that was approved by the institutional review board of Sir Run Run Shaw Hospital (Zhejiang, China) and Huashan Hospital (Shanghai, China), and an informed consent form was obtained from the patient before the study. Minimum inhibitory concentrations of colistin (0.5 mg/L) and sulbactam (128 mg/L) were determined by broth microdilution.
Free full text: Click here
